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Research Submission
Efficacy of  Galcanezumab for Migraine Prevention in Patients 
With a Medical History of  Anxiety and/or Depression: A Post 
Hoc Analysis of  the Phase 3, Randomized, Double-Blind, 
Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and 
EVOLVE-2 Studies
Todd A. Smitherman, PhD ; Gretchen E. Tietjen, MD; Kory Schuh, PhD; Vladimir Skljarevski, MD;  
Sarah Lipsius, MS; Deborah N. D’Souza, PhD; Eric M. Pearlman, MD, PhD
Objective.—This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine in patients with 
and without comorbid anxiety and/or depression.
Background.—Patients with migraine have a higher risk of anxiety and/or depression. Given the high prevalence of psy-
chiatric symptoms and their potential negative prognostic impact, determining the efficacy of migraine treatments in patients 
with these comorbidities is important.
Methods.—The results of 2 phase 3 episodic migraine studies of patients with 4-14 migraine headache days (MHD) per 
month were pooled. A third chronic migraine study, which was evaluated separately, enrolled patients with ≥15 headache days 
per month, of which ≥8 had migraine-like features. Patients in all 3 studies were randomized 2:1:1 to placebo, galcanezumab 
120  mg, or galcanezumab 240  mg. The efficacy of galcanezumab on migraine was measured in subgroups of patients with 
anxiety and/or depression (current or past) and patients without. A repeated measures model was used to compare treatment 
groups within each subgroup and to test for consistency of treatment effect across the anxiety/depression subgroups (subgroup-
by-treatment interaction) during the double-blind treatment phases.
Results.—Among 1773 intent-to-treat patients with episodic migraine, both doses of galcanezumab demonstrated statistically 
significant improvements relative to placebo in overall number of MHD for the subgroups of patients with anxiety and/or depression 
(mean change difference from placebo [95% CI]: −2.07 [−2.81, −1.33] for galcanezumab 120  mg [P  <  .001], −1.91 [−2.78, −1.04] 
for 240 mg [P <  .001]) and without anxiety and/or depression (mean change difference from placebo [95% CI]: −1.92 [−2.36, −1.47] 
for 120  mg [P  <  .001], −1.77 [−2.20, −1.33] for 240  mg [P  <  .001]), as was observed for the secondary outcomes of MHD with 
acute medication use and functional impairment. Among 1113 intent-to-treat patients with chronic migraine, those with anxiety and/
or depression had significant reductions in overall MHD frequency with the 240-mg dose (mean change difference from placebo 
[95% CI]: −1.92 [−3.52, −0.33]; P  =  .018), whereas significant reductions were observed at both the 120-mg (mean change 
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difference from placebo [95% CI]: −2.29 [−3.26, −1.31]; P  <  .001) and 240-mg (−1.85 [−2.83, −0.87]; P  <  .001) doses in patients 
without anxiety and/or depressions. Significant reductions (P <  .01) in MHD with acute medication use were observed at both doses 
within both anxiety/depression subgroups and for overall functional impairment for patients without anxiety and/or depression, though 
neither dose significantly reduced overall functional impairment beyond placebo in the subgroup with anxiety and/or depression. In 
the episodic and chronic migraine studies, the subgroup-by-treatment interaction was not statistically significant for MHD, MHD 
with acute medication use, or functional impairment (chronic study only), suggesting a lack of evidence of differential effect between 
subgroups. Furthermore, differences between subgroups in the mean change differences from placebo, as well as overlapping 95% 
confidence intervals for the subgroups, indicated lack of a clinical or statistical difference between subgroups for these outcome 
variables. There was a significantly higher percentage of patients with episodic migraine attaining ≥50%, ≥75%, and 100% reduc-
tions, and a higher percentage of patients with chronic migraine attaining ≥50% and ≥75% reductions from baseline with galcanezumab 
compared with placebo, regardless of medical history of anxiety and/or depression.
Conclusions.—A medical history of anxiety and/or depression does not seem to interfere with response to galcanezumab 
among patients with episodic migraine, and both doses of galcanezumab appear efficacious for these individuals regardless of 
this psychiatric history. Among patients with chronic migraine and comorbid anxiety and/or depression, the 240-mg dose, but 
not the 120-mg dose, significantly decreased overall MHD, but neither dose resulted in significantly greater functional improve-
ment. Patients with migraine and comorbid anxiety and/or depression often require additional interventions, and this may be 
more important in chronic migraine.
Key words: galcanezumab, migraine, comorbid, anxiety, depression, prevention
Abbreviations:  ANOVA analysis of  variance, CGRP calcitonin gene-related peptide, IHS International Headache Society, 
ICHD-3 International Classification of  Headache Disorders-3rd edition, MIDAS Migraine Disability 
Assessment, MHD migraine headache days, MMRM mixed model repeated measures, MSQ Migraine-
Specific Quality of  life Questionnaire
(Headache 2020;60:2202-2219)
INTRODUCTION
Migraine is a chronic, debilitating neurological dis-
ease that affects approximately 12% of the world’s popu-
lation1 and is the second highest cause of years lost due to 
disability globally.2 Although more than 25% of patients 
with migraine could benefit from preventive therapy,3 
only a fraction of patients receive preventive treatment.
Numerous studies have shown that migraine carries 
increased risk for comorbid psychiatric disorders, partic-
ularly anxiety4,5 and depression,6 such that risk for these 
conditions is more than double compared with patients 
without migraine.7-9 The prevalence of comorbid psy-
chiatric conditions is highest among those with chronic 
(vs episodic) migraine.10 Comorbid anxiety and depres-
sion account for a substantial portion of role disability 
in migraine,11 increase the risk for migraine progression 
over time,12 and have been associated with poor response 
to both acute and preventive migraine pharmacother-
apies.13,14,15 Given the high prevalence of comorbid 
psychiatric symptoms in patients with migraine, it is 
important to understand the efficacy of novel treatments 
for those with comorbid anxiety and/or depression.
Calcitonin gene-related peptide (CGRP) has been 
strongly implicated in the pathophysiology of mi-
graine,16 and a number of small-molecule CGRP recep-
tor antagonists and monoclonal antibodies to CGRP 
have shown efficacy as CGRP-targeted therapies for 
migraine.16-18 Galcanezumab is a humanized monoclo-
nal antibody that binds to CGRP and prevents its bio-
logical activity without blocking the CGRP receptor.19 
Galcanezumab is FDA approved for preventive treat-
ment of migraine in adults. In phase 3 studies, galcane-
zumab at both 120-mg and 240-mg doses was shown to 
significantly reduce the number of migraine headache 
days (MHD) compared with placebo in patients with 
episodic migraine20,21 and chronic migraine.22 Given 
the results from recent trials of galcanezumab and 
high rates of psychiatric comorbidities in migraine, the 
Conflict of Interest: TAS has served as a consultant for Alder. GET has no conflicts of interest. KS, VS, and EMP are full-time employ-
ees and minor stock holders of Eli Lilly and Company. SL and DND are full-time employees of Syneos Health.
Funding: This study was funded by Eli Lilly and Company, Indianapolis, IN, USA.
ClinicalTrials.gov identifier: EVOLVE-1 (NCT02614183), EVOLVE-2 (NCT02614196), and REGAIN (NCT02614261)
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present post hoc analysis sought to evaluate the efficacy 
of galcanezumab for preventive treatment of migraine 
in patients with comorbid anxiety and/or depression.
METHODS
In this post hoc analysis of 3 randomized, double-
blind, placebo-controlled, phase 3 studies, data from 2 
episodic migraine studies were pooled; the chronic mi-
graine study was analyzed separately. The efficacy of 
galcanezumab was evaluated both within and between 
the subgroups of patients who had anxiety and/or de-
pression and those who did not. Anxiety and/or depres-
sion were determined by a medical history taken by each 
investigator (patient reported experiencing anxiety and/
or depression in the past and/or currently) and by re-
view of available medical records. The 2 studies that were 
pooled, EVOLVE-1 (NCT02614183)20 and EVOLVE-2 
(NCT02614196),21 were designed to examine whether gal-
canezumab at doses of 120 or 240 mg per month was su-
perior to placebo in the preventive treatment of episodic 
migraine. The third study, REGAIN (NCT02614261),22 
was designed to determine whether galcanezumab at 
doses of 120 or 240 mg per month was superior to pla-
cebo in the preventive treatment of chronic migraine. The 
trial study designs are shown in Figure 1, and more infor-
mation is available in the primary manuscripts.20-22 The 
study protocols were approved by the institutional review 
board for each study site, and patients provided written 
informed consent before undergoing study procedures.
Patients were included in the anxiety/depression 
subgroup if  their medical history or medical record in-
cluded coded terms specific to 1 or more anxiety and 
depression diagnosis, and were either ongoing (“cur-
rent”) or in the past, that is, resolved prior to random-
ization (“past only”). Anxiety-related terms included 
anxiety, agoraphobia, phobia of flying, social anxiety 
disorder, panic disorder, generalized anxiety disorder, 
anxiety disorder, panic attack, panic reaction, and 
adjustment disorder with anxiety.  Depression-related 
terms included depression, adjustment disorder with 
depressed mood, premenstrual dysphoric disorder, 
major depression, perinatal depression, depressive 
symptom, depressed mood, persistent depressive dis-
order, and menopausal depression. Concomitant med-
ication indications were not collected, so it was not 
possible to determine which patients were being treated 
for anxiety and/or depression.
Participants.—All 3 studies included patients who 
were 18-65 years of  age with onset of  migraine pri-
or to age 50 and excluded patients who had failed 
to respond to 3 or more classes of  adequately dosed 
migraine preventive treatments with Level A or Level 
B evidence for efficacy.23 In addition, EVOLVE-1 and 
EVOLVE-2 included patients who met criteria for a 
diagnosis of  migraine with or without aura. Patients 
had a diagnosis of  migraine as defined by Interna-
tional Headache Society (IHS) International Classifi-
cation of  Headache Disorders-3rd edition (ICHD-3), 
Fig. 1.—Study design. Galcanezumab (GMB); once monthly (QMT); randomization (R); subcutaneous (SC). *All patients had the 
option of receiving GMB with flexible dosing (120 or 240 mg) decided at the discretion of the investigator.
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beta.24 They had a history of  migraine headaches for 
at least 1 year prior to visit 1 and a history of  4-14 
MHD per month occurring during at least 2 migraine 
attacks per month on average over the past 3 months. 
Randomization was stratified by region/country and 
baseline migraine frequency (<8 MHD vs ≥8 MHD). 
These studies were conducted at 199 study sites in 
12 countries.
The REGAIN study included patients diagnosed 
with chronic migraine as defined by the IHS ICHD-3 
beta guidelines (1.3):24 headache occurring on 15 or 
more days per month for more than 3 months, which 
has the features of migraine headache on at least 
8 days per month. Prior to Visit 1, patients had to have 
a history of at least 1 headache-free day per month for 
the past 3  months. Randomization was stratified by 
country, acute headache medication overuse (yes/no) 
as determined during the prospective baseline period, 
and use of concurrent migraine prophylactic medica-
tion (yes/no). This study was conducted at 117 sites in 
12 countries.
Outcome Measures.—In all 3 studies, the prima-
ry outcome was overall mean change from baseline 
in the number of monthly MHD. The term “over-
all” denotes the average treatment effect during the 
double-blind treatment period, which was estimated 
from the mixed model repeated measures (MMRM) 
analysis model. The number of MHD, number of MHD 
with acute medication use, and scores on the Role Func-
tion-Restrictive domain of the Migraine-Specific Qual-
ity of Life Questionnaire (MSQ)25,26 were also exam-
ined on a monthly basis. Scores on this subscale of the 
MSQ quantify role impairment resulting from migraine 
on a 0-100 scale, with higher scores indicating better 
functioning. Since no analyses were conducted to de-
termine the appropriate responder thresholds for other 
domains of the MSQ, analyses to support the tertiary 
objective for categorical change in other MSQ domains 
(Role Function-Preventive and Emotional Function) 
were not conducted. Response rates (50%, 75%, and 
100% reduction from baseline in monthly MHD) were 
also examined by month and overall.
Statistical Analyses.—All analyses were conducted 
on the intent-to-treat population which included ran-
domized patients who received at least 1 dose of study 
drug. As the efficacy outcomes analyzed changes from 
baseline, patients must have had a nonmissing base-
line and post-baseline value to be included in the anal-
ysis at a particular month. For the analysis of MHD, 
MHD with acute medication use, and MSQ Role Func-
tion-Restrictive domain score, differences from place-
bo in least squares mean changes from baseline are pre-
sented for galcanezumab 120 and 240 mg along with 
associated 95% confidence intervals. Figures display 
least square mean changes from baseline and associat-
ed 95% confidence intervals for the placebo, galcane-
zumab 120, and 240 mg groups.
Analyses within subgroups of  MHD, MHD with 
acute medication use, and MSQ Role Function-
Restrictive domain score were conducted using a 
MMRM approach with terms for treatment, base-
line value, pooled country, month, treatment-by-
month, and baseline-by-month. For the pooled 
episodic studies, a term for study was also included. 
The model used to compare subgroups had addi-
tional terms for subgroup, subgroup-by-treatment, 
subgroup-by-month, and subgroup-by-treatment-
by-month. For the chronic migraine study, addi-
tional covariates of  baseline medication overuse as 
determined during the prospective baseline period, 
and concurrent prophylaxis use were added to both 
models just as was done for the analyses within the 
primary publication. Response rates were analyzed 
using a categorical, pseudolikelihood-based repeated 
measures model for binary outcomes similar to the 
models described above except without the pooled 
country term, so as to avoid convergence problems. 
Continuous demographic and baseline characteris-
tics, all of  which were ratio variables, were compared 
between treatment groups using a 1-way analysis of 
variance (ANOVA) with treatment in the model, and 
between subgroups using a 1-way ANOVA with anxi-
ety/depression subgroup in the model. An additional 
term for study was added to the model for the pooled 
episodic studies. The number of  failed migraine pre-
ventative treatments, an ordinal variable, was com-
pared between treatments and subgroups using the 
Cochran-Mantel-Haenszel test (adjusted for study, 
for the pooled episodic studies).
For demographic and baseline variables analyzed 
using parametric tests (eg, ANOVA), the normality 
assumption was assessed using Q-Q plots. Sensitivity 
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analyses were performed on the primary outcome 
(change from baseline in MHD) to assess the potential 
impact of missing data assumptions and the robust-
ness of MMRM results to deviations from normality. 
The results of these sensitivity analyses were consistent 
with the primary analysis.
Treatment effects were evaluated based upon a 
2-sided, .05 significance level. The subgroup-by-treat-
ment interaction was tested at a 2-sided, .1 signifi-
cance level. All statistical analyses were performed 
using SAS Enterprise Guide 7.1 (SAS Institute, 
Cary, NC).
RESULTS
Baseline Characteristics.—Anxiety and/or depression 
was reported in 26.0% of  patients with episodic 
migraine (461/1773 patients) and 28.4% of  patients 
with chronic migraine (316/1113 patients). The 
majority of  these patients (77% [357/461] of  pa-
tients with episodic migraine and 81% [257/316] of 
patients with chronic migraine) reported ongoing 
anxiety and/or depression at randomization (“cur-
rent”); the remaining patients had anxiety and/or de-
pression that resolved prior to randomization (“past 
only”; median symptom resolution occurred 4 years 
prior to study enrollment). In the episodic migraine 
studies, patients with anxiety and/or depression 
(compared with patients without anxiety and/or de-
pression) had a significantly greater number of  con-
ditions comorbid with migraine (P  <  .001), signifi-
cantly lower MSQ Role Function-Restrictive domain 
scores (P = .038), and significantly higher Migraine 
Disability Assessment (MIDAS)27,28 total scores 
(P  <  .001). In addition, patients with episodic mi-
graine with anxiety and/or depression were slightly 
older (P = .044) and had more MHD (P = .046) and 
MHD with acute medication use (P  =  .013) com-
pared with patients without anxiety and/or depres-
sion (Table 1).
In the chronic migraine study, the patients with 
anxiety and/or depression had a greater number of 
migraine comorbidities (P  <  .001), lower MSQ Role 
Function-Restrictive domain scores (P = .003), higher 
MIDAS total score (P = .003), and a greater number 
of MHD (P = .036), compared with patients without 
anxiety and/or depression (Table 2).
There were no significant differences in the num-
ber of failed migraine preventative treatments (none, 
1-3, and ≥4) between the subgroups with anxiety and/
or depression vs those without in the episodic migraine 
studies or in the chronic migraine study.
Migraine Headache Days.—In the episodic migraine 
studies, both doses of galcanezumab demonstrated sta-
tistically significant improvements compared with pla-
cebo in the overall (months 1-6) and monthly change 
from baseline in the number of MHD in patients with 
anxiety and/or depression and patients without (overall 
mean change difference from placebo [95% CI]: −2.07 
[−2.81, −1.33] for galcanezumab 120  mg [P  <  .001], 
−1.91 [−2.78, −1.04] for 240 mg [P < .001] in patients 
with anxiety and/or depression; −1.92 [−2.36, −1.47] 
for galcanezumab 120  mg [P  <  .001], −1.77 [−2.20, 
−1.33] for 240 mg [P < .001] in patients without anxi-
ety and/or depression) (Table 3) (Fig. 2A,B). Overlap-
ping 95% confidence intervals indicated that treatment 
effects were not statistically different between the sub-
groups. Subgroup differences in these mean change 
differences of −0.15 for galcanezumab 120  mg and 
−0.14 for 240 mg were not clinically significant. Fur-
thermore, the comparison of both doses of galcane-
zumab was not statistically significant within the sub-
groups, and the subgroup-by-treatment interaction 
was not statistically significant (P = .827).
In the chronic migraine study, statistically sig-
nificant improvements in the number of  MHD were 
seen in the subgroup with anxiety and/or depression 
for galcanezumab 240  mg compared with placebo 
overall (mean change difference from placebo [95% 
CI]: −1.92 [−3.52, −0.33] [P = .018]) but not for gal-
canezumab 120 mg (−1.50 [−3.15, 0.15] [P =  .074]), 
and for both galcanezumab doses compared with 
placebo at month 1 (Fig. 3A). Both doses of  galca-
nezumab also demonstrated statistically significant 
improvements compared with placebo in the overall 
(months 1-3) and monthly change from baseline in 
the number of  MHD in the subgroup without anx-
iety and/or depression (overall mean change differ-
ence from placebo [95% CI]: −2.29 [−3.26, −1.31] 
for galcanezumab 120  mg [P  <  .001], −1.85 [−2.83, 
−0.87] for 240 mg [P < .001]) (Fig. 3B). Overlapping 
95% CIs between the subgroups as well as small sub-
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































0.79 and −0.07 for galcanezumab 120 and 240  mg, 
respectively, indicated lack of  a clinically meaning-
ful or statistical difference. Treatment comparisons 
of  both doses of  galcanezumab were not statistically 
significant within the subgroups overall or monthly. 
The subgroup-by-treatment interaction was not sta-
tistically significant (P = .697).
MHD With Acute Medication Use.—In the epi-
sodic migraine studies, both doses of  galcanezumab 
demonstrated statistically significant improvements 
compared with placebo in the number of  MHD with 
acute medication use overall in the subgroup with 
anxiety and/or depression and the subgroup with-
out (subgroup with anxiety and/or depression, mean 
change difference from placebo [95% CI]: −1.88 
[−2.53, −1.22] for galcanezumab 120 mg [P < .001], 
−1.86 [−2.57, −1.14] for 240 mg [P < .001]; subgroup 
without anxiety and/or depression: −1.79 [−2.18, 
−1.40] for galcanezumab 120  mg [P  <  .001], −1.62 
[−2.00, −1.24] for 240 mg [P < .001]) (Table 3). The 
monthly change from baseline in the number of 
MHD with acute medication use in both subgroups 
Fig. 2.—Overall and monthly change from baseline in number of migraine headache days (episodic migraine studies). Subgroup-by-
treatment P value = .827; Subgroup-by-treatment interaction: .60 (GAL 120 mg vs PBO), .627 (GAL 240 mg vs PBO), .997 (GAL 
240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01 vs PBO. Galcanezumab (GAL); number of patients (N); placebo (PBO); standard 
error (SE). 
Fig. 3.—Overall and monthly change from baseline in number of migraine headache days (chronic migraine study). Subgroup-by-
treatment P value = .697; Subgroup-by-treatment interaction: 0.447 (GAL 120 mg vs PBO), 0.918 (GAL 240 mg vs PBO), 0.451 
(GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01, *P ≤ .05 vs PBO. Galcanezumab (GAL); number of patients (N); placebo 
(PBO); standard error (SE). 
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paralleled the overall results (Fig.  4A,B). Overlap-
ping 95% confidence intervals and small subgroup 
differences in the mean change differences from pla-
cebo of  −0.09 and −0.24 for galcanezumab 120 and 
240  mg, respectively, suggested that there were no 
clinically meaningful or statistically significant dif-
ferences between subgroups. Treatment compari-
sons of  both doses of  galcanezumab were not sta-
tistically significant within the subgroups, and the 
subgroup-by-treatment interaction was not statisti-
cally significant (P = .751).
Similarly, among patients with chronic migraine 
with anxiety and/or depression and without, both doses 
of galcanezumab outperformed placebo overall in the 
number of MHD with acute medication use (subgroup 
with anxiety and/or depression, mean change differ-
ence from placebo [95% CI]: −2.19 [−3.68, −0.69] for 
galcanezumab 120 mg [P = .004], −1.94 [−3.39, −0.50] 
for 240 mg [P = .009]; subgroup without anxiety and/or 
depression, mean change difference from placebo [95% 
CI]: −2.59 [−3.47, −1.70] for galcanezumab 120  mg 
[P < .001], −2.06 [−2.95, −1.16] for 240 mg [P < .001]) 
(Table 4) (Fig. 5A,B). Overlapping 95% confidence in-
tervals indicated that overall treatment effects were not 
statistically different between the subgroups. Subgroup 
differences in these mean change differences of 0.4 for 
galcanezumab 120 mg and 0.12 for 240 mg were not 
clinically significant. For patients with anxiety and/
or depression, galcanezumab 120  mg was superior 
to placebo at all months and 240 mg was superior at 
month 1 (Fig. 5A). For patients without anxiety and/
or depression, MHD with acute medication use were 
significantly reduced with both doses of galcanezumab 
at all months (Fig. 5B). Within the subgroups, galcane-
zumab 120 mg did not differ significantly from 240 mg 
overall. In addition, the subgroup-by-treatment inter-
action was not significant (P = .937).
Functional Impairment (MSQ Role Function-Re-
strictive Domain).—For patients with episodic mi-
graine with anxiety and/or depression and patients 
without, there was a significantly greater mean im-
provement in the overall (subgroup with anxiety and/
or depression, mean change difference from placebo 
[95% CI]: 10.37 [7.45, 13.29] for galcanezumab 120 mg 
[P < .001], 8.44 [5.07, 11.82] for 240 mg [P < .001]; sub-
group without anxiety and/or depression: 7.49 [5.64, 
9.34] for galcanezumab 120 mg [P < .001], 7.06 [5.26, 
8.87] for 240  mg [P  <  .001]) (Table  3), and monthly 
change from baseline in the MSQ Role Function- 
Restrictive domain score for both galcanezumab dos-
es compared with placebo (Fig.  6A,B). Overlapping 
95% confidence intervals and small subgroup differ-
ences in the mean change differences from placebo of 
2.88 and 1.38 for galcanezumab 120 and 240 mg, re-
spectively, indicated a lack of clinically or statistically 
significant differences between subgroups. Treatment 
Fig. 4.—Overall and monthly change from baseline in number of migraine headache days with acute medication use (episodic migraine 
studies). Subgroup-by-treatment P value  =  .751; Subgroup-by-treatment interaction: 0.700 (GAL 120  mg vs PBO), 0.458 (GAL 
240 mg vs PBO), 0.736 (GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01   vs PBO. Galcanezumab (GAL); number of patients 












































































































































































































































































































































































































































































































































































































































































comparisons of both doses of galcanezumab were not 
statistically significant within the subgroups. There 
was a statistically significant subgroup-by-treatment 
interaction (P  =  .018) for the average of months 4-6 
for galcanezumab 120 mg compared with placebo, but 
this interaction was deemed spurious and not clini-
cally meaningful, as neither the subgroup-by-treat-
ment interaction for galcanezumab 240  mg vs place-
bo, nor the overall (months 1-6) interaction was statistically 
significant (P = .187). Furthermore, the direction of the 
treatment effect (for the average of months 4-6) for the 
galcanezumab 120-mg-minus-placebo difference was 
consistent across the subgroups.
In the chronic migraine study, in patients with 
anxiety and/or depression, there was a significantly 
greater improvement in the mean change from base-
line on the MSQ Role Function-Restrictive domain 
score in the galcanezumab 240-mg group compared 
Fig. 5.—Overall and monthly change from baseline in number of migraine headache days with acute medication use (chronic migraine 
study). Subgroup-by-treatment P value = .937; Subgroup-by-treatment interaction: 0.719 (GAL 120 mg vs PBO), 0.890 (GAL 240 mg 
vs PBO), 0.845 (GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01, *P ≤ .05 vs PBO. Galcanezumab (GAL); number of patients 
(N); placebo (PBO); standard error (SE). 
Fig. 6.—Overall and monthly change from baseline in MSQ role function-restrictive domain score (episodic migraine studies). 
Subgroup-by-treatment P value = .187; Subgroup-by-treatment interaction (Average of months 4 to 6): 0.018 (GAL 120 mg vs PBO), 
0.308 (GAL 240 mg vs PBO), 0.280, (GAL 240 mg vs GAL 120 mg), ***P ≤  .001        vs PBO. Galcanezumab (GAL); Migraine-
Specific Quality of life Questionnaire (MSQ); number of patients (N); placebo (PBO); standard error (SE). 
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with placebo only at month 1; however, there was no 
significant improvement relative to placebo in the 
overall change from baseline at either dose (mean 
change difference from placebo [95% CI]: 2.59 [−2.69, 
7.87] for galcanezumab 120 mg [P = .335]; 5.04 [−0.07, 
10.15] for 240 mg [P = .053]) (Fig. 7A). For patients 
without anxiety and/or depression, there was a sig-
nificantly greater improvement in the overall (mean 
change difference from placebo [95% CI]: 5.94 [2.85, 
9.02] for galcanezumab 120 mg [P < .001]; 7.84 [4.73, 
10.95] for 240 mg [P < .001]) (Table 4), and monthly 
changes from baseline on the MSQ Role Function-
Restrictive domain score in both the galcanezumab 
120-mg and 240-mg treatment groups compared with 
placebo (Fig. 7B). Overall treatment effects were not 
statistically different between the subgroups as indi-
cated by overlapping 95% confidence intervals, and 
small subgroup differences in mean change differ-
ences of  −3.35 and −2.8 for galcanezumab 120 and 
240  mg, respectively, were not clinically significant. 
Within the subgroups, galcanezumab 120 mg did not 
differ significantly from 240  mg overall. The sub-
group-by-treatment interaction was not significant 
(P = .515).
50%, 75%, and 100% Reduction in Monthly MHD.—
Among patients with episodic migraine and anxi-
ety and/or depression, 59% of patients in the galcane-
zumab 120-mg (N = 127) and 240-mg groups (N = 99), 
compared with 36% (N = 227) of patients in the pla-
cebo group, had ≥50% reduction from baseline (“50% 
response”) in MHD overall (P ≤ .001) (Fig. 8A). Simi-
lar results were seen in the group without anxiety and/
or depression (61% and 58% for galcanezumab 120 mg 
[N = 309] and 240 mg [N = 329], respectively, vs 38% in 
placebo [N = 648] overall; P ≤ .001) (Fig. 8B). The 50% 
response rates at each month were significantly greater 
with both galcanezumab doses compared with place-
bo in both anxiety/depression subgroups (Fig. 8A,B). 
Within the subgroups, galcanezumab 120 mg did not 
differ significantly from 240  mg overall. The sub-
group-by-treatment interaction was not significant 
(P = .822).
Among patients with chronic migraine and anxi-
ety and/or depression, 21% (N = 75) and 27% (N = 80) 
of patients receiving galcanezumab 120 mg (P = .040) 
and 240 mg (P = .001), respectively, vs 13% (N = 156) 
of patients receiving placebo, had ≥50% reduction 
from baseline in MHD overall (Fig.  9A). Similar re-
sults were seen in patients without anxiety and/or 
depression (30% [N = 198] and 28% [N = 194] of pa-
tients receiving galcanezumab 120 mg [P <  .001] and 
240  mg [P  <  .001], respectively, vs 17% [N  =  382] in 
placebo overall) (Fig. 9B). Monthly 50% response rates 
were significantly greater with both galcanezumab 
doses in patients without anxiety and/or depression; 
in the subgroup with anxiety and/or depression, 50% 
Fig. 7.—Overall and monthly change from baseline in MSQ role function-restrictive domain score (chronic migraine study). Subgroup-
by-treatment P value = .515; Subgroup-by-treatment interaction (month 3): 0.849 (GAL 120 mg vs PBO), 0.478 (GAL 240 mg vs 
PBO), 0.437 (GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01   vs PBO. Galcanezumab (GAL); Migraine-Specific Quality of 
life Questionnaire (MSQ); number of patients (N); placebo (PBO); standard error (SE). 
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response rates were significantly greater than placebo 
in the galcanezumab 240-mg group at all visits and 
at month 1 in the galcanezumab 120-mg group. The 
subgroup-by-treatment interaction was not significant 
(P = .428).
Monthly 75% response rates also favored those 
receiving either dose of galcanezumab compared with 
placebo, in both patients with episodic migraine and 
chronic migraine, regardless of comorbid anxiety and/
or depression. Approximately 35% of patients with 
episodic migraine and anxiety and/or depression who 
received either dose of galcanezumab (N  =  127 for 
galcanezumab 120 mg and N = 99 for galcanezumab 
240 mg) had ≥75% reduction from baseline in MHD 
overall vs 17% for placebo (N  =  227) (P  <  .001). 
Similar results were seen in the group without anxiety 
and/or depression (approximately 36% for galcane-
zumab 120 mg [N = 309] and 37% for galcanezumab 
Fig. 8.—Overall and monthly percentage of patients with ≥50% reduction in monthly MHD (episodic migraine studies).† Subgroup-
by-treatment P value = .822; Subgroup-by-treatment interaction: 0.566 (GAL 120 mg vs PBO), 0.585 (GAL 240 mg vs PBO), 0.920, 
(GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01, *P ≤ .05 vs PBO. †Using Model Estimated Rate (SE). Galcanezumab (GAL); 
migraine headache days (MHD); number of patients (N); placebo (PBO); standard error (SE). 
Fig. 9.—Overall and monthly percentage of patients with ≥50% reduction in monthly MHD (chronic migraine study).† Subgroup-
by-treatment P value = .428; Subgroup-by-treatment interaction: 0.210 (GAL 120 mg vs PBO), 0.350 (GAL 240 mg vs PBO), 0.690 
(GAL 240 mg vs GAL 120 mg), ***P ≤ .001, **P ≤ .01, *P ≤ .05 vs placebo. †Using Model Estimated Rate (SE). Galcanezumab 
(GAL); migraine headache days (MHD); number of patients (N); placebo (PBO); standard error (SE). 
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240  mg [N  =  329], respectively, vs 19% in placebo 
[N = 648] overall; P < .001 for both doses vs placebo). 
Among those with chronic migraine and anxiety and/
or depression, a significantly greater proportion of pa-
tients receiving 240-mg galcanezumab compared with 
placebo achieved ≥75% overall MHD reduction from 
baseline (approximately 8% [N = 80] vs 4% [N = 156], 
respectively, P  =  .025). A greater proportion of pa-
tients receiving either galcanezumab dose achieved 
≥75% overall MHD reduction from baseline compared 
with placebo, among patients with chronic migraine 
without anxiety and/or depression (approximately 8% 
[N = 198] and 9% [N = 194] for galcanezumab 120 mg 
[P = .028] and 240 mg [P = .009], respectively, vs 5% 
[N = 382] in placebo overall).
In the episodic migraine studies, in the subgroup 
with anxiety and/or depression, 13% of patients in the 
galcanezumab 120-mg (N = 127) and 240-mg (N = 99) 
groups, vs 6% in the placebo group (N  =  227), had 
100% reduction from baseline (“100% response”) in 
MHD overall (P  <  .001). Similar results were seen 
in the subgroup without anxiety and/or depression 
(14% and 15% for galcanezumab 120  mg [N  =  309] 
and 240 mg [N = 329], respectively, vs 6% in placebo 
[N = 648] overall [P < .001]). In the chronic migraine 
study, in the subgroup with anxiety and/or depression, 
the analysis model did not converge for the analysis of 
100% response. In the subgroup without anxiety and/
or depression, there was no significant difference from 
placebo in the percentage of patients who had 100% 
reduction from baseline in MHD overall (0.8% and 
1.6% for galcanezumab 120 mg [N = 198] and 240 mg 
[N = 194], respectively, vs 0.8% [N = 382] in placebo).
DISCUSSION
This post hoc analysis evaluated the efficacy of 
galcanezumab among patients with either episodic or 
chronic migraine as a function of anxiety and/or de-
pression. In patients with episodic migraine, both gal-
canezumab doses yielded significant improvements 
compared with placebo across clinical (reductions in 
MHD, MHD with acute medication use, MHD re-
sponse rates) and functional outcomes pertaining to 
quality of life, regardless of anxiety and/or depression 
suggesting that the treatment effect was not mean-
ingfully impacted by the presence of anxiety and/or 
depression. The majority of patients with episodic mi-
graine who received galcanezumab reported at least a 
50% reduction in migraine frequency, compared with 
slightly more than one-third of those receiving pla-
cebo, irrespective of anxiety and/or depression.
The positive treatment effects and lack of signif-
icant or meaningful subgroup-by-treatment inter-
actions suggest that galcanezumab is efficacious in 
reducing migraine headache and improving quality 
of life among patients with episodic migraine, regard-
less of whether comorbid anxiety and/or depression is 
present. Studies have shown that treatment satisfac-
tion perceived by patients with either anxiety alone 
or anxiety with depression is lower than in patients 
without these comorbid conditions,13 and higher anxi-
ety is associated with a lower probability of treatment 
response.14 Although a recent study suggested that 
depression is associated with inadequate response to 
preventive migraine pharmacotherapy, specifically 
Onabotulinumtoxin A for chronic migraine,15 our data 
do not indicate that anxiety and/or depression confer 
risk for poor response to galcanezumab, at least among 
patients with episodic migraine. Instead, they add to 
a small but growing body of studies suggesting that 
patients with migraine and anxiety and/or depression 
respond well to preventive pharmacotherapy or behav-
ioral interventions for migraine.29-31
The efficacy of galcanezumab for adults with 
chronic migraine and anxiety and/or depression was 
not as consistent as that observed among patients with 
episodic migraine. Both doses of galcanezumab out-
performed placebo on all outcome measures among 
patients with chronic migraine without anxiety and/
or depression. Among patients with chronic migraine 
and anxiety and/or depression, improvements in most 
clinical outcomes (ie, MHD, MHD with acute medica-
tion use, 50% MHD response rates) over placebo were 
evident, though only the 240-mg dose outperformed 
placebo on the primary outcome of MHD. However, 
among patients with chronic migraine with anxiety 
and/or depression, reductions in headache were not re-
flected in differential improvements in role functioning 
beyond placebo.
A high placebo response, apparent in these and 
other trials of preventive agents targeting CGRP,32 
does not appear responsible for this variability, as 
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superiority over placebo on most other outcome vari-
ables emerged despite high placebo response and as 
patients with chronic migraine without anxiety and/or 
depression demonstrated greater functional improve-
ment vs placebo at both doses of galcanezumab. The 
decoupling of clinical improvement and functional 
outcomes as measured by the MSQ has been observed 
previously among individuals with chronic migraine 
receiving topiramate33 and was thus not entirely un-
expected. Perhaps differential functional improvement 
would be evident with a greater observed reduction in 
MHD, a longer duration of treatment, or use of an 
outcome measure that more broadly quantifies func-
tional impairment (eg, incorporating assessment of 
emotional functioning or changes in psychiatric symp-
toms over time). As, to our knowledge, this is the first 
study of an agent targeting CGRP to compare head-
ache outcomes as a function of psychiatric symptoms, 
further investigation is clearly warranted to better 
clarify the effects among individuals with chronic mi-
graine and anxiety and/or depression. Such patients 
may also benefit from combining galcanezumab with 
evidence-based behavioral interventions (eg, stress 
management, relaxation, or biofeedback) that focus on 
teaching coping skills with applicability to psychiatric 
symptoms.34,35
Strengths of this study include the large sample 
sizes, utilization of ICHD-3 beta diagnostic criteria, 
and rigorous randomized-controlled trials multisite 
design. The most notable limitation of this study is 
that presence of anxiety and/or depression was deter-
mined via baseline medical interview and review of 
records rather than assessment of established diag-
nostic criteria, as the studies were not originally de-
signed to address questions of psychiatric comorbidity. 
Furthermore, since the indication for concomitant 
medication use was not recorded, it was not possible 
to determine which patients received medications for 
anxiety and/or depression. Although a more rigorous 
psychiatric evaluation would have been achieved via 
administration of a structured diagnostic interview or 
validated psychiatric questionnaires, the observed rates 
of anxiety and/or depression (roughly one-quarter of 
the sample) approximate those obtained within the 
American Migraine Prevalence and Prevention study.10
Another limitation is that this was a post hoc 
analysis of 3 trials, so the studies were not originally 
designed to compare the comorbidity subgroups. 
Therefore, failing to find statistically significant sub-
group-by-treatment interactions is not conclusive ev-
idence of absence of a differential subgroup effect in 
light of reduced statistical power. Although the stud-
ies were not powered to compare treatment groups as 
a function of anxiety and/or depression, the results 
suggest that the sample size for episodic migraine was 
adequate to address these questions. However, the sam-
ple size of the chronic migraine subgroup with anxiety 
and/or depression was the smallest, which may have re-
sulted in reduced power to detect treatment effects. The 
fact that the criteria of the clinical trials excluded per-
sons failing more than 2 classes of Level A/B migraine 
preventive medications may limit the generalizability to 
persons who have been refractory to 3 or more preven-
tive medications. Finally, these studies did not assess 
changes in psychiatric symptoms over time as a func-
tion of treatment, and thus, the effect of galcanezumab 
on psychiatric symptoms is unknown. Future studies 
should endeavor to assess psychiatric symptoms over 
time to determine whether galcanezumab favorably 
impacts comorbid psychiatric symptoms in addition 
to headache variables and whether addition of a be-
havioral intervention might yield more substantial im-
provements among patients with chronic migraine and 
anxiety and/or depression.
CONCLUSION
The prevention of migraine remains an impor-
tant unmet clinical need, particularly among the many 
patients with comorbid psychiatric symptoms. The 
results of these 3 phase 3 clinical trials suggest that, 
regardless of medical history of comorbid anxiety and/
or depression, galcanezumab is efficacious for reduc-
ing migraine frequency and improving quality of life 
among those with episodic migraine. Among those 
with chronic migraine and comorbid anxiety and/or 
depression, only the 240-mg dose significantly reduced 
migraine frequency, but neither dose differentially im-
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